Home › Neuroblastoma
Neuroblastoma clinical trials recruiting in the U.S.
50 studies for Neuroblastoma are recruiting participants at sites across the United States.
Neuroblastoma is a cancer in nerve tissue in the adrenal gland, neck, chest, or spinal cord. It often affects young children. Read about treatments.
Cities with the most studies
- Boston, MA13 studies
- New York City, NY12 studies
- Washington, DC11 studies
- Dallas, TX10 studies
- Cincinnati, OH9 studies
- St. Louis, MO9 studies
- Memphis, TN9 studies
- Philadelphia, PA9 studies
- Aurora, CO9 studies
- Hartford, CT8 studies
- Birmingham, AL8 studies
- Harrisburg, PA8 studies
- Minneapolis, MN8 studies
- Gainesville, FL7 studies
- Orlando, FL7 studies
- Miami, FL7 studies
- Los Angeles, CA7 studies
- Atlanta, GA7 studies
- San Francisco, CA7 studies
- Chicago, IL7 studies
- Durham, NC6 studies
- Oakland, CA6 studies
- Honolulu, HI6 studies
- Salt Lake City, UT6 studies
- Seattle, WA6 studies
- Greenburgh, NY6 studies
- Little Rock, AR6 studies
- Portland, OR6 studies
- Houston, TX6 studies
- Nashville, TN5 studies
- Charleston, SC5 studies
- San Diego, CA5 studies
- Columbus, OH5 studies
- Ann Arbor, MI5 studies
- Mountain View, CA5 studies
- Austin, TX5 studies
- Louisville, KY4 studies
- St. Petersburg, FL4 studies
- Kansas City, MO4 studies
- Milwaukee, WI4 studies
By state
- Alabama8 studies
- Arizona3 studies
- Arkansas6 studies
- California15 studies
- Colorado9 studies
- Connecticut9 studies
- District of Columbia6 studies
- Florida10 studies
- Georgia9 studies
- Hawaii6 studies
- Illinois7 studies
- Indiana3 studies
- Iowa3 studies
- Kentucky5 studies
- Maryland8 studies
- Massachusetts13 studies
- Michigan8 studies
- Minnesota9 studies
- Missouri10 studies
- New Jersey6 studies
- New York15 studies
- North Carolina7 studies
- North Dakota3 studies
- Ohio10 studies
- Oklahoma3 studies
- Oregon6 studies
- Pennsylvania16 studies
- Rhode Island3 studies
- South Carolina6 studies
- South Dakota3 studies
- Tennessee12 studies
- Texas15 studies
- Utah6 studies
- Virginia3 studies
- Washington6 studies
- Wisconsin6 studies
Recently updated studies
Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
Recruiting
Up to age 17 · All sexes · Updated Nov 13, 2026 · NCT06831552Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RecruitingPhase 1/2
Up to age 30 · All sexes · Updated Nov 12, 2026 · NCT06541262Naxitamab Enabled Transplant-Free Study in High-Risk Neuroblastoma
RecruitingPhase 2
Ages 1 to 30 · All sexes · Updated Nov 12, 2026 · NCT07932808A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
RecruitingPhase 2Healthy volunteers welcome
All ages · All sexes · Updated Nov 10, 2026 · NCT04936529A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
RecruitingPhase 2
All ages · All sexes · Updated Nov 9, 2026 · NCT06057948A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Nov 9, 2026 · NCT06041516Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
RecruitingPhase 1/2
Ages 1 to 30 · All sexes · Updated Nov 6, 2026 · NCT07437963Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
RecruitingObservational study
Ages 4 and older · All sexes · Updated Nov 5, 2026 · NCT01005654PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy
RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Nov 4, 2026 · NCT04837547Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
RecruitingPhase 3
Up to age 30 · All sexes · Updated Oct 30, 2026 · NCT06172296Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Oct 30, 2026 · NCT06395103Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
RecruitingPhase 2
Up to age 30 · All sexes · Updated Oct 27, 2026 · NCT02605421Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RecruitingPhase 1
7 Months – 21 Years · All sexes · Updated Oct 27, 2026 · NCT02508038International PPB/DICER1 Registry
RecruitingObservational studyHealthy volunteers welcome
0 Minutes – 100 Years · All sexes · Updated Oct 26, 2026 · NCT03382158Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
RecruitingPhase 1
Ages 3 to 35 · All sexes · Updated Oct 21, 2026 · NCT06995872Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
RecruitingObservational studyHealthy volunteers welcome
4 Weeks · All sexes · Updated Oct 16, 2026 · NCT01109394Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
RecruitingPhase 1
12 Months – 20 Years · All sexes · Updated Oct 8, 2026 · NCT02013336PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
RecruitingPhase 1/2
Ages 1 to 30 · All sexes · Updated Oct 6, 2026 · NCT06721689Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
RecruitingObservational study
All ages · All sexes · Updated Oct 5, 2026 · NCT00588068MCT for the Harvard/UCSF ROBIN Center
Recruiting
All ages · All sexes · Updated Oct 1, 2026 · NCT06000787Biomarkers of Resiliency In Childhood Cancer Surgery
RecruitingObservational study
Ages 3 to 25 · All sexes · Updated Sep 14, 2026 · NCT06674811Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
RecruitingPhase 2
Up to age 22 · All sexes · Updated Sep 4, 2026 · NCT02559778B7-H3.CD28Z.CART in Solid Tumors
RecruitingPhase 1
9 Months – 30 Years · All sexes · Updated Sep 3, 2026 · NCT07358260Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
RecruitingPhase 2
Ages 1 to 21 · All sexes · Updated Sep 3, 2026 · NCT06540963International Congenital Central Hypoventilation Syndrome (CCHS) Registry and CCHS SHARE
RecruitingObservational study
All ages · All sexes · Updated Sep 3, 2026 · NCT03088020From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.